05/19/22 8:05 AMNasdaq : MBRX conferencesMoleculin to Present at the H.C. Wainwright Global Investment ConferenceMoleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and ChiefRHEA-AIneutral
05/12/22 8:35 AMNasdaq : MBRX earningsMoleculin Reports First Quarter 2022 Financial Results and Provides Programs Update– Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies –– Multiple key clinical and regulatory milestones expected throughout 2022 –– Company has sufficient capital to fund operations into 2024 –HOUSTON , May 12, 2022RHEA-AIpositive
05/10/22 8:35 AMNasdaq : MBRX clinical trialcovid-19Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), aRHEA-AIneutral
05/05/22 8:15 AMNasdaq : MBRX clinical trialMoleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)– Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine– Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine combined compared to Annamycin as a single agentRHEA-AIpositive
05/04/22 8:15 AMNasdaq : MBRX Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical OfficerGlobal leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomasCompany continues to advance clinical development across priority development pipeline withRHEA-AIvery positive
04/21/22 8:47 AMNasdaq : MBRX clinical trialMoleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant GliomaMoleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company withRHEA-AIneutral
04/14/22 8:05 AMNasdaq : MBRX Moleculin Announces Corporate Rebranding and Launch of New WebsiteMoleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or theRHEA-AIpositive
04/11/22 7:05 AMNasdaq : MBRX /C O R R E C T I O N -- Moleculin Biotech, Inc./In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised by the company that the second paragraph following the details section, third sentence, shouldRHEA-AIpositive
04/08/22 1:05 PMNasdaq : MBRX Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual MeetingMoleculinRHEA-AIpositive
03/25/22 7:05 AMNasdaq : MBRX earningsMoleculin Reports Full Year Financial Results and Provides Programs Update– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine –– Preliminary interim data for Annamycin in three Phase 1 clinical trials for Acute Myeloid Leukemia (AML) and metastases of Soft TissueRHEA-AIpositive